89Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: Implications for future cancer therapy

Linda Karmani, Virginie Bouchat, Caroline Bouzin, Philippe Levêque, Daniel Labar, Anne Bol, Gladys Deumer, Riccardo Marega, Davide Bonifazi, Vincent Haufroid, Carine Michiels, Vincent Grégoire, Olivier Feron, Stéphane Lucas, Thierry Vander Borght, Bernard Gallez

Résultats de recherche: Contribution à un journal/une revueArticle

4 Downloads (Pure)

Résumé

Aims: Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting. Materials & methods: Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers. Results: The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation. Conclusion: The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection. Original submitted 29 April 2013; Revised submitted 20 September 201.

langue originaleAnglais
Pages (de - à)1923-1937
Nombre de pages15
journalNanomedicine
Volume9
Numéro de publication13
Les DOIs
étatPublié - 2014

Empreinte digitale

Antibodies
Gold
Nanoparticles
Tumors
Anti-Idiotypic Antibodies
Imaging techniques
Neoplasms
Therapeutics
Immunoconjugates
Endoglin
Antibody Specificity
Plasmas
Injections

Citer ceci

@article{9d9b2282aaa0404c9f79ef1daa501018,
title = "89Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer: Implications for future cancer therapy",
abstract = "Aims: Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting. Materials & methods: Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers. Results: The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation. Conclusion: The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection. Original submitted 29 April 2013; Revised submitted 20 September 201.",
keywords = "Zr, anti-endoglin antibody-targeted gold nanoparticles, biodistribution, cancer, CD105, immuno-PET, molecular imaging",
author = "Linda Karmani and Virginie Bouchat and Caroline Bouzin and Philippe Lev{\^e}que and Daniel Labar and Anne Bol and Gladys Deumer and Riccardo Marega and Davide Bonifazi and Vincent Haufroid and Carine Michiels and Vincent Gr{\'e}goire and Olivier Feron and St{\'e}phane Lucas and {Vander Borght}, Thierry and Bernard Gallez",
year = "2014",
doi = "10.2217/nnm.13.185",
language = "English",
volume = "9",
pages = "1923--1937",
journal = "Nanomedicine",
issn = "1743-5889",
publisher = "Future Medicine Ltd.",
number = "13",

}

89Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer : Implications for future cancer therapy. / Karmani, Linda; Bouchat, Virginie; Bouzin, Caroline; Levêque, Philippe; Labar, Daniel; Bol, Anne; Deumer, Gladys; Marega, Riccardo; Bonifazi, Davide; Haufroid, Vincent; Michiels, Carine; Grégoire, Vincent; Feron, Olivier; Lucas, Stéphane; Vander Borght, Thierry; Gallez, Bernard.

Dans: Nanomedicine, Vol 9, Numéro 13, 2014, p. 1923-1937.

Résultats de recherche: Contribution à un journal/une revueArticle

TY - JOUR

T1 - 89Zr-labeled anti-endoglin antibody-targeted gold nanoparticles for imaging cancer

T2 - Implications for future cancer therapy

AU - Karmani, Linda

AU - Bouchat, Virginie

AU - Bouzin, Caroline

AU - Levêque, Philippe

AU - Labar, Daniel

AU - Bol, Anne

AU - Deumer, Gladys

AU - Marega, Riccardo

AU - Bonifazi, Davide

AU - Haufroid, Vincent

AU - Michiels, Carine

AU - Grégoire, Vincent

AU - Feron, Olivier

AU - Lucas, Stéphane

AU - Vander Borght, Thierry

AU - Gallez, Bernard

PY - 2014

Y1 - 2014

N2 - Aims: Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting. Materials & methods: Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers. Results: The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation. Conclusion: The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection. Original submitted 29 April 2013; Revised submitted 20 September 201.

AB - Aims: Antibody-labeled gold nanoparticles represent an attractive tool for cancer imaging and therapy. In this study, the anti-CD105 antibody was conjugated with gold nanoparticles (AuNPs) for the first time. The antibody biodistribution in mice before and after conjugation to AuNPs was studied, with a focus on tumor targeting. Materials & methods: Antibodies were radiolabeled with 89Zr before conjugation to AuNPs (5 nm). Immunonanoconjugates were characterized in vitro in terms of size, stability in plasma and binding to the target. Quantitative PET imaging and ICP-MS analysis assessed in vivo distribution and specific tumor targeting of tracers. Results: The tumor uptake of immunoconjugates was preserved up to 24 h after injection, with high tumor contrast and selective tumor targeting. No major tracer accumulation was observed over time in nonspecific organs. ICP-MS analysis confirmed the antibody specificity after nanoparticle conjugation. Conclusion: The anti-CD105 antibody conjugation to AuNPs did not greatly affect CD105-dependent tumor uptake and the efficacy of tumor targeting for cancer detection. Original submitted 29 April 2013; Revised submitted 20 September 201.

KW - Zr

KW - anti-endoglin antibody-targeted gold nanoparticles

KW - biodistribution

KW - cancer

KW - CD105

KW - immuno-PET

KW - molecular imaging

UR - http://www.scopus.com/inward/record.url?scp=84908281139&partnerID=8YFLogxK

U2 - 10.2217/nnm.13.185

DO - 10.2217/nnm.13.185

M3 - Article

AN - SCOPUS:84908281139

VL - 9

SP - 1923

EP - 1937

JO - Nanomedicine

JF - Nanomedicine

SN - 1743-5889

IS - 13

ER -